Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
- 30 September 2006
- journal article
- review article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 55 (3), 449-459
- https://doi.org/10.1016/j.jaad.2006.05.009
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximabBritish Journal of Dermatology, 2005
- Role of intramolecular epitope spreading in pemphigus vulgarisClinical Immunology, 2005
- Progression of classic Kaposi's sarcoma with rituximabJournal of the American Academy of Dermatology, 2005
- Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigusBritish Journal of Dermatology, 2005
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative DisorderLeukemia & Lymphoma, 2003
- Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatmentJournal of the American Academy of Dermatology, 2001
- Cytotoxic agents for use in dermatology. IJournal of the American Academy of Dermatology, 1985
- Cyclophosphamide (Cytoxan): A review on relevant pharmacology and clinical usesJournal of the American Academy of Dermatology, 1984
- Pemphigus and pemphigoid: A review of the advances made since 1964Journal of the American Academy of Dermatology, 1979